^
    3d
    Intrapulmonary Biphasic Mesothelioma Misdiagnosed as Adenocarcinoma: Case Report and a Potential Diagnostic Pitfall. (PubMed, Onco Targets Ther)
    The patient was treated with a chemotherapy regimen of pemetrexed and carboplatin. Mesothelioma with predominantly intrapulmonary growth is extremely rare and poses a diagnostic pitfall. For this entity, subtle morphological features, selection of immunohistochemical markers, and electron microscopy are of great significance for definite diagnosis.
    Journal
    |
    WT1 (WT1 Transcription Factor) • CD34 (CD34 molecule) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    TTF1 negative
    |
    carboplatin • pemetrexed
    3d
    RMC-LUNG-101: Study of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC (clinicaltrials.gov)
    P1/2, N=484, Recruiting, Revolution Medicines, Inc. | N=352 --> 484
    Enrollment change • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • RMC-6236 • RMC-6291
    4d
    Peri-E: Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    carboplatin • Tyvyt (sintilimab) • pemetrexed
    5d
    A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) (clinicaltrials.gov)
    P3, N=726, Not yet recruiting, mAbxience Research S.L.
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • MB12 (pembrolizumab biosimilar)
    5d
    ARC-10: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (clinicaltrials.gov)
    P2, N=169, Active, not recruiting, Arcus Biosciences, Inc. | Phase classification: P3 --> P2 | Trial primary completion date: Aug 2024 --> May 2027
    Phase classification • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    6d
    A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=750, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    6d
    Intrathecal Pemetrexed for Leptomeningeal Metastasis (clinicaltrials.gov)
    P1/2, N=34, Completed, The First Hospital of Jilin University | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2024
    Trial completion • Trial completion date
    |
    pemetrexed • dexamethasone injection
    8d
    The Effectiveness and Safety of Sintilimab Plus Bevacizumab Combined with Pemetrexed and Platinum-Based Drugs in Retrospective Analysis for Advanced Non-Small Cell Lung Cancer Patients Without Targeted Therapy (ChiCTR2400089107)
    P4, N=100, Not yet recruiting, Anhui Chest Hospital; Anhui Chest Hospital
    New P4 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK fusion • ALK mutation • RET mutation • ROS1 fusion • ROS1 mutation
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • pemetrexed
    8d
    Neoadjuvant hypofractioned radiotherapy followed by benmelstobart plus chemotherapy for resectable non-small cell lung cancer: A phase II study (ChiCTR2400089423)
    P1, N=150, Recruiting, Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
    New P1 trial
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • benmelstobart (APL-502)
    10d
    Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (clinicaltrials.gov)
    P2, N=40, Recruiting, Istituto Oncologico Veneto IRCCS | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed
    11d
    Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients. (PubMed, Transl Lung Cancer Res)
    The tumor growth inhibitory rate was 99.36% for dabrafenib, trametinib, and osimertinib; 99.25% for osimertinib plus vemurafenib; 98.92% for osimertinib, encorafenib, and cetuximab; and 62.83% for pemetrexed plus carboplatin. NGS analysis identified major resistance mechanisms following the triple-targeted therapy, including the EGFR-dependent pathway, EGFR and BRAF V600E-dependent pathway, and an off-target mechanism. EGFR/BRAF/MEK triple-targeted therapy is an effective and safe approach for treating EGFR-mutated NSCLC patients resistant to EGFR-TKIs with acquired BRAF V600E mutations.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • EGFR mutation • BRAF V600
    |
    Erbitux (cetuximab) • Mekinist (trametinib) • Tagrisso (osimertinib) • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • carboplatin • Braftovi (encorafenib) • pemetrexed
    11d
    Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50. (PubMed, Transl Lung Cancer Res)
    All first-line treatments applied pembrolizumab (median dose: 12 cycles)...Of the patients with PRs or CRs, 75% were treated with platinum plus pemetrexed...The current response to second-line platinum-based therapies for patients with advanced NSCLC after immunotherapy appears to achieve favourable response rates and be an optimal treatment after progression to immunotherapy. Prior immunotherapy appears to enhance these patients' platinum response, though future confirmatory studies are necessary.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK mutation
    |
    Keytruda (pembrolizumab) • pemetrexed
    11d
    STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors (clinicaltrials.gov)
    P1, N=202, Recruiting, Synthekine | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • STK-012
    12d
    Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment (clinicaltrials.gov)
    P1, N=18, Terminated, The Netherlands Cancer Institute | N=34 --> 18 | Trial completion date: Jan 2021 --> Nov 2024 | Unknown status --> Terminated | Trial primary completion date: Jan 2021 --> Nov 2024; Based on initially defined safety rules not continued with expansion phase of study (too much toxicity with neo-adjuvant immunotherapy)
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    cisplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab) • pemetrexed
    13d
    A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov)
    P1, N=830, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • leucovorin calcium • MK-1084
    14d
    A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, TYK Medicines, Inc
    New P2 trial • Metastases
    |
    cisplatin • carboplatin • pemetrexed • asandeutertinib (TY-9591)
    17d
    BFAST: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2/3, N=1000, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • gemcitabine • Rozlytrek (entrectinib) • docetaxel • Alecensa (alectinib) • Cotellic (cobimetinib) • pemetrexed • divarasib (RG6330)
    18d
    HORIZON 2: A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Hoffmann-La Roche | Trial completion date: Nov 2034 --> Mar 2033 | Trial primary completion date: Oct 2029 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Alecensa (alectinib) • pemetrexed
    18d
    BGB-LC-202: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=121, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • LBL-007
    18d
    A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (clinicaltrials.gov)
    P3, N=680, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • mRNA-4157
    18d
    COPERNICUS: A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=365, Not yet recruiting, Janssen Research & Development, LLC
    New P2 trial • Combination therapy • Metastases
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC)
    19d
    First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation. (PubMed, BMC Cancer)
    The results of this study demonstrate that the four-drug combination regimen, led by gefitinib, is manageable and tolerated and effective for patients with EGFR-mutated advanced non-squamous NSCLC.
    Journal • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Avastin (bevacizumab) • carboplatin • gefitinib • pemetrexed
    19d
    The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity. (PubMed, EBioMedicine)
    This study provides a mechanistic rationale to clinical evidence correlating the poor outcome of patients with mesothelioma and with eosinophil-derived CLC-P/Gal10, opening new prospects for intervention in this fatal solid tumour.
    Journal
    |
    LGALS1 (Galectin 1)
    |
    cisplatin • pemetrexed
    20d
    TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. (PubMed, Future Oncol)
    We describe the rationale and design of TROPION-Lung07, a randomized, open-label Phase III study assessing Dato-DXd in combination with pembrolizumab with/without platinum-based chemotherapy versus pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with advanced/metastatic non-squamous NSCLC without actionable genomic alterations and <50% PD-L1 expression. Primary study objectives are progression-free survival and overall survival.Clinical Trial Registration: NCT05555732 (ClinicalTrials.gov).
    P3 data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • pemetrexed • datopotamab deruxtecan (DS-1062a)
    20d
    Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC (clinicaltrials.gov)
    P1, N=19, Recruiting, Shanghai Chest Hospital
    New P1 trial
    |
    Avastin (bevacizumab) • pemetrexed
    21d
    BTCRC-LUN19-396: Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) (clinicaltrials.gov)
    P2, N=100, Recruiting, Nasser Hanna | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Tecentriq (atezolizumab) • docetaxel • pemetrexed
    21d
    Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Shanghai Chest Hospital
    New P2 trial • Combination therapy
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed
    21d
    TROPION Lung15: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=630, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • datopotamab deruxtecan (DS-1062a)
    24d
    Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC. (PubMed, BMC Cancer)
    The combination of spartalizumab and PDC, with or without canakinumab, was well tolerated across treatment groups. The antitumor activity across treatment groups was comparable with that of pembrolizumab and pemetrexed combination. Canakinumab did not appear to improve the antitumor activity when combined with spartalizumab, pemetrexed and cisplatin.
    Journal • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • spartalizumab (PDR001) • Ilaris (canakinumab)
    25d
    CHRYSALIS-2: A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=701, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=460 --> 701
    Enrollment closed • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation • EGFR expression + MET expression
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    26d
    HARMONIC: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (clinicaltrials.gov)
    P2, N=90, Recruiting, Lantern Pharma Inc. | Trial completion date: May 2025 --> Jun 2026 | Trial primary completion date: Nov 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    carboplatin • pemetrexed • Tavocept (dimesna)
    28d
    Radiation Toxicity in MDA5+ and PL7-Positive Dermatomyositis: Heightened Risk in Autoimmune Subtypes. (PubMed, Int J Part Ther)
    He received 4 cycles of pemetrexed/cisplatin with proton therapy (PT) delivered halfway through for a bronchial stump positive margin. Immunosuppressive agents given with RT may be considered for patients with autoimmune disease. Avoidance of biopsy, tissue manipulation, debridement, or any form of soft-tissue or hard-tissue violation needs to be discussed across the multidisciplinary spectrum to avoid nonhealing lesions shortly after RT.
    Journal
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    cisplatin • pemetrexed
    28d
    MCC-21-NEURO-11: Pembro+Chemo in Brain Mets (clinicaltrials.gov)
    P2, N=3, Terminated, John L. Villano, MD, PhD | Trial completion date: May 2033 --> Dec 2023 | Active, not recruiting --> Terminated; Slow Accrual
    Trial completion date • Trial termination
    |
    PD-1 (Programmed cell death 1)
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    29d
    Targeted and cytotoxic inhibitors used in the treatment of lung cancers. (PubMed, Pharmacol Res)
    On the order of 20% of NSCLCs bear activating mutations in EGFR and are treated with osimertinib and other kinase antagonists...Local treatment options to control thoracic disease include radiotherapy and surgery. In patients with extensive-stage disease, a platinum agent (cisplatin or carboplatin) combined with etoposide and an anti-PDL1 inhibitor (atezolizumab or durvalumab) for four cycles followed by anti-PDL1 maintenance therapy is the recommended first-line regimen.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • BRAF mutation • ALK translocation
    |
    Mekinist (trametinib) • cisplatin • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Retevmo (selpercatinib) • pemetrexed • etoposide IV • Tabrecta (capmatinib)
    1m
    DIAL: De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction (clinicaltrials.gov)
    P2/3, N=1360, Recruiting, Intergroupe Francophone de Cancerologie Thoracique | Trial primary completion date: Jun 2024 --> Jan 2025
    Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • pemetrexed
    1m
    DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Oct 2024 --> Jan 2025
    Trial initiation date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed
    1m
    EF-001: A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy. (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Shandong Cancer Hospital and Institute
    New trial
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • etoposide IV • Ryzneuta (efbemalenograstim alpha)
    1m
    The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study). (PubMed, JTO Clin Res Rep)
    Platinum plus pemetrexed had the best overall survival benefits after osimertinib. Nevertheless, osimertinib should be discontinued among those who develop progression. UMIN000038683.
    Journal • Real-world evidence • Real-world effectiveness • Real-world • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • pemetrexed
    1m
    CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov)
    P1, N=1200, Recruiting, Amgen | Trial completion date: Jun 2029 --> Mar 2028 | Trial primary completion date: Jan 2027 --> Apr 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • zeluvalimab (AMG 404)
    1m
    KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) (clinicaltrials.gov)
    P1/2, N=450, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • patritumab deruxtecan (U3-1402) • ifinatamab deruxtecan (DS-7300) • vibostolimab (MK-7684) • MK-0482 • MK-4830
    1m
    The Growth of A549 Cell Line is Inhibited by Pemetrexed Through Up-regulation of hsa-MiR-320a Expression. (PubMed, Adv Biomed Res)
    Identifying these MicroRNAs can be helpful in predicting the efficacy of the chemotherapy or introducing it as combination therapy. Our research has been shown that hsa-MiR-320a can serve as a biomarker of PMX efficacy and also has the potential to be used in combination therapy.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MIR320A (MicroRNA 320a) • VDAC1 (Voltage Dependent Anion Channel 1)
    |
    BAX expression • miR-320a expression
    |
    pemetrexed
    1m
    TRITON: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov)
    P3, N=280, Recruiting, AstraZeneca | Trial completion date: Oct 2032 --> Mar 2031
    Trial completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab) • pemetrexed